验证数据展示
经过测试的应用
| Positive WB detected in | U2OS cells |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
24435-1-AP targets L3MBTL2 in WB, ELISA applications and shows reactivity with human samples.
| 经测试应用 | WB, ELISA Application Description |
| 经测试反应性 | human |
| 免疫原 |
CatNo: Ag19571 Product name: Recombinant human L3MBTL2 protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 284-427 aa of BC017191 Sequence: RTIHAKFTDWKGYLMKRLVGSRTLPVDFHIKMVESMKYPFRQGMRLEVVDKSQVSRTRMAVVDTVIGGRLRLLYEDGDSDDDFWCHMWSPLIHPVGWSRRVGHGIKMSERRSDMAHHPTFRKIYCDAVPYLFKKVRAVYTEGGW 种属同源性预测 |
| 宿主/亚型 | Rabbit / IgG |
| 抗体类别 | Polyclonal |
| 产品类型 | Antibody |
| 全称 | l(3)mbt-like 2 (Drosophila) |
| 别名 | L(3)mbt-like protein 2, L(3)mbt like protein 2, l(3)mbt like 2 (Drosophila), H-l(3)mbt-like protein 2, H l(3)mbt like protein 2 |
| 计算分子量 | 705 aa, 79 kDa |
| 观测分子量 | 95-100 kDa |
| GenBank蛋白编号 | BC017191 |
| 基因名称 | L3MBTL2 |
| Gene ID (NCBI) | 83746 |
| RRID | AB_3085733 |
| 偶联类型 | Unconjugated |
| 形式 | Liquid |
| 纯化方式 | Antigen affinity purification |
| UNIPROT ID | Q969R5 |
| 储存缓冲液 | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| 储存条件 | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
L3MBTL2 (Lethal (3) malignant brain tumor like 2) is a member of the MBT-domain proteins, which are involved in transcriptional repression and implicated in chromatin compaction. L3MBTL2 was most highly expressed in pachytene spermatocytes within the testis (PMID: 30760872).In addition, mutations in L3MBTL2 are prevalent in various cancers including leukemia, a disease characterized by alterations in multiple DNA repair proteins (PMID: 29581593).
实验方案
| Product Specific Protocols | |
|---|---|
| WB protocol for L3MBTL2 antibody 24435-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
